Ovarian and breast cancer spheres are similar in transcriptomic features and sensitive to fenretinide

Haiwei Wang1, Yuxing Zhang, Yanzhi Du

  • 1Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) and Shanghai Jiao Tong University School of Medicine (SJTU-SM), 225 Chong-Qing South Road, Shanghai 200025, China ; Graduate School of the Chinese Academy of Sciences, Beijing 100049, China.

Insights

Cancer stem cells (CSCs) exhibit chemotherapy resistance and tumor regeneration capabilities. This study identifies shared CSC mechanisms in ovarian and breast cancers, highlighting fenretinide as a potential therapeutic agent.

Area of Science:

  • Oncology
  • Cancer Biology
  • Cellular Mechanisms

Background:

  • Cancer stem cells (CSCs) are crucial drivers of tumor growth and treatment resistance.
  • Understanding CSC heterogeneity and therapeutic vulnerabilities is critical for effective cancer treatment.

Purpose of the Study:

  • To characterize sphere cells from ovarian and breast cancer cell lines as models for CSCs.
  • To investigate the molecular pathways involved in CSC genesis across different cancer types.
  • To evaluate the efficacy of fenretinide as a potential CSC-targeting therapy.

Main Methods:

  • Characterization of ovarian cancer sphere cells for CSC features (drug resistance, tumor initiation).
  • cDNA microarray analysis of sphere cells from ovarian and breast cancer lines.
  • Assessment of fenretinide sensitivity in cancer sphere cells.

Main Results:

  • Ovarian cancer sphere cells displayed key CSC characteristics, including cisplatin resistance and efficient tumor initiation.
  • Molecular pathway analysis revealed significant similarities in CSC genesis between ovarian and breast cancer cells.
  • Cancer sphere cells demonstrated high sensitivity to fenretinide, inducing oxidative stress-mediated apoptosis.

Conclusions:

  • Shared molecular mechanisms underlie CSC development in ovarian and breast cancers.
  • Fenretinide shows promise as a therapeutic agent targeting CSCs through oxidative stress induction.
  • These findings offer insights for developing novel cancer therapies targeting CSCs.